MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

Raychaudhuri, Mithu; Bronger, Holger; Buchner, Theresa; Kiechle, Marion; Weichert, Wilko; Avril, Stefanie

doi:10.1007/s10549-017-4132-9

User: Guest

journal article

Title:: MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Document type:: Journal Article
Author(s):: Raychaudhuri, Mithu; Bronger, Holger; Buchner, Theresa; Kiechle, Marion; Weichert, Wilko; Avril, Stefanie
Abstract:: miRNAs have been linked to chemosensitivity of breast cancer cells in vitro. In patients, however, there is no clinically validated method for predicting chemotherapy response. The aim of this study was to assess whether (I) a specific pattern of miRNA expression in pretherapeutic biopsies can predict response to neoadjuvant chemotherapy, and (II) differential miRNA expression in residual tumor after completion of chemotherapy allows further prognostic stratification of non-responding patients.Sixty-four patients with newly diagnosed large (>=3 cm) or locally advanced primary breast cancers who underwent neoadjuvant anthracycline/taxane-based chemotherapy were included. Relative expression of 10 miRNAs likely to be associated with chemotherapy response (miR-7,-21,-29a,-29b,-34a,-125b,-155,-200c,-340,-451) was determined by quantitative RT-PCR from pretherapeutic biopsies (n = 64) and residual invasive tumor after chemotherapy (n = 42). Pathologic complete response (pCR) defined by absence of invasive tumor served as reference standard. In addition, miRNA expression was compared with disease-free and overall survival.Nine (14%) of 64 patients achieved pCR. High expression of miR-7 and low expression of miR-340 in pretherapeutic biopsies predicted pCR with a negative predictive value of 96 and 97%, respectively (specificity 54 and 57%). The combined profile of miR-7(high)/miR-340(low) demonstrated improved specificity of 86% while maintaining a high negative predictive value (96%) to identify non-responders. Pretherapeutic expression of miR-200c and miR-155 showed prognostic information, and low expression was associated with increased overall survival (115 vs. 90 months, p <= 0.03). After chemotherapy, the overall survival of patients with residual invasive tumor was better for those demonstrating low miR-7 or high miR-125b (p = 0.01).Intratumoral expression of miR-7 and miR-340 prior to neoadjuvant chemotherapy could be used to predict pCR and a profile of miR-7(low) or miR-340(high) identified patients unlikely to achieve pCR who might benefit from alternative treatment options including earlier surgery. Our study identifies miRNAs as promising predictive biomarkers, which could aid in optimization of breast cancer management and treatment stratification.
Journal title abbreviation:: Breast Cancer Res Treat
Year:: 2017
Journal volume:: 162
Journal issue:: 3
Pages contribution:: 511-521
Language:: eng
Fulltext / DOI:: doi:10.1007/s10549-017-4132-9
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/28181130
Print-ISSN:: 0167-6806
TUM Institution:: Frauenklinik und Poliklinik; Institut für Allgemeine Pathologie und Pathologische Anatomie
BibTeX